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Abstract
In life-threatening conditions such as cancer and rare diseases, where there is no cure and no U.S. Food and Drug
Administration (FDA)-approved therapy, patients sometimes seek access to an unapproved, experimental therapy
through expanded access programs as their last, best hope for treatment to save their lives. Since the 1980s, the
policies and the practice of expanded access have evolved, but a common challenge remains that there is no
obligation, and often little incentive, for manufacturers to offer expanded access programs, especially for individual
patients. In recent years, online campaigns seeking access to an experimental therapy have become more common,
paralleling growth in and representing an intersection of social media, digital health, and patient advocacy.
Mackey and Schoenfeld have examined the evolution of expanded access policy, practice, and trends, as well as
case studies of online campaigns to access experimental therapies, to arrive at several recommendations for the
future of expanded access. This commentary puts their paper in context, examines their recommendations, and
suggests further reforms.
Please see related article: https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-016-0568-8
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Background
Mackey and Schoenfeld examined the evolution of ex-
panded access policy in the United States, as well as
more recent trends toward alternative access such as
“right-to-try” legislation and social media campaigns [1].
They discussed both the ethical and practical concerns
behind manufacturer denials of expanded access [1].
There is no legal obligation for manufacturers to pro-
vide experimental therapies to patients prior to U.S.
Food and Drug Administration (FDA) approval outside
of a qualifying clinical trial [2]. In the absence of such an
obligation, and in light of other perceived impediments
to accessing promising therapies, patient advocates have
sought alternative means of access via lawsuits, state and
federal legislative and regulatory reforms, and publicity.
Some reforms seek to loosen the restrictions involved in
the FDA expanded access program (EAP) requirements,
while others seek to obligate or pressure manufacturers
to provide experimental therapies to patients individually
or through an EAP. There is little correlation of factors
that point to a “winning” strategy for obtaining such ac-
cess [1]. Significantly, manufacturers, advocacy organiza-
tions, and the FDA each appear to be in search of a new
paradigm that ethically and practically addresses patient
and manufacturer concerns.
Social media campaigns for expanded access: an
intersection of trends
In an era where the average person spends over 6 hours
per day online, including 1.72 hours on social media [3],
we see the percentage of people who manage aspects of
their health online continue to grow, from self-diagnosis
via search engines to fitness apps to online access to
medical records [4]. Similarly, the already growing trend
of social media engagement has begun to intersect with
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digital health in areas such as social aspects of fitness
tracker and dieting apps and even crowdsourcing diagno-
ses [5, 6]. Finally, a third trend, the rise of patient advo-
cacy, has also paralleled and been influenced by the above
trends in digital health and social media [7, 8].
Therefore, it should not surprise us when potentially
life-saving recourse is also sought online via social media.
Online campaigns seeking access to unapproved therapies
offer hope for individuals and families facing a devastating
diagnosis for which there is no alternative treatment.
Although a wide range of success and failure results
from such campaigns, their proliferation results from the
intersection and symbiotic relationship among trends in
social media, digital health, and patient advocacy as shown
in Fig. 1.
In addition, patient advocates have become increasingly
vocal in campaigns for legislative or regulatory changes that
purport to offer easier access to experimental therapies for
patients and families facing life-threatening diagnoses, such
as right-to-try bills and FDA regulatory reforms.
Against the backdrop of those individual and policy
campaigns, pharmaceutical companies, regulatory agen-
cies, and commentators have also begun attempting to
shift the paradigm for accessing experimental therapies
[9–11]. The question is whether those efforts, and others
that may follow, are sufficiently disruptive forces that will
alter the growth and sophistication of online campaigns
for experimental therapies.
Expanded access: evolution or revolution?
Mackey and Schoenfeld examined the ethical and prac-
tical questions posed by the evolving landscape of access
to experimental therapies, identifying and analyzing
the impact of a spectrum of social media campaigns,
the right-to-try legislative movement, and the existing
regulatory framework [1].
They accurately elucidate many of the pivotal points in
the evolution of expanded access: 1) the issuance of FDA
regulations regarding expanded access during the HIV/
AIDS cases in the early 1980s; 2) the 2001 formation of
the Abigail Alliance and its subsequent litigation; 3) the
landmark 2008 decision of the U.S. Court of Appeals for
the D.C. Circuit ruling that patients did not have the con-
stitutional right to access experimental drugs; and 4) the
evolution of FDA guidance on expanded access categories
and processes from 2009 to 2013 and new revisions in
2015 [1]. I would add a most recent pivotal point involving
one of the prominent social media campaign case studies,
the 2014 Josh Hardy–Chimerix case. In that case, the very
public promotion and resulting success of the campaign in
accessing the experimental therapy (and the resulting
positive outcome for the young patient, who recovered
after receiving the drug) appeared to publicly validate
social media as a promising strategy when alternatives
have failed [9].
The Josh Hardy campaign illustrates that the most
common hurdle to patient access is often not the FDA,
which approves the vast majority (99 %) of expanded
access requests it receives, most of which are for
single-patient emergency or non-emergency use [12].
Instead, the critical challenge for most patients seeking
expanded access is obtaining the approval of the manufac-
turer of the therapy. It is the refusal of manufacturers to
provide access that becomes the subject of most patient
and caregiver social media campaigns seeking expanded
access.
The rationale offered by manufacturers for denying ex-
panded access requests generally fall into one or more of
the following: limited safety and efficacy data; limited
supply of medication; the need to focus financial,
personnel, and other resources toward clinical trials and
drug approval; the potential impact on clinical trial en-
rollment; concern over potential poor outcomes and
the effect upon the drug’s development of reporting of
adverse events to FDA; as well as the ethical dilemma
of expanding access to one or more patients versus an
entire community [13].
Patient case studies
Mackey and Schoenfeld identified 23 recent U.S. patient
case studies who sought expanded access to experimental
treatment and coded each for types of platforms used,
use of multimedia, number of signatures obtained (for
Fig. 1 The intersection of trends in social media, digital health, and
patient advocacy. The popularity of online social media campaigns
to access experimental therapies operate in the shaded area where
the trends of social media, digital health, and patient advocacy
intersect. Absent a disruptive force, as these three trends continue,
such campaigns will likely increase and grow more sophisticated in
their implementation
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campaigns using online petitions), category of disease
addressed, type of treatment requested, and name of
company/organization petitioned [1].
Although their analysis was able to identify two common
themes: 1) a common narrative among the campaigns of
the denied drug representing their last and best hope for a
life-saving intervention; and 2) the trend of higher petition
signatures/social engagement correlating with greater
national news attention, there was no correlation among
factors supporting a particular “winning” strategy for
obtaining access to the sought therapy [1].
Implications for patients and policy
The Mackey and Schoenfeld study has potential implica-
tions both for patients as well as policy reforms. In part
due to the success of the Hardy–Chimerix case and
others, and absent a disruptive force, the trend of patient
social media campaigns for expanded access will likely
only increase. The strategies employed by the patient
case studies will be replicated and improved upon by the
next campaign and the one thereafter. The patchwork
of proffered solutions by many parties might improve
aspects of the expanded access system, such as patient
education, patient–treatment match, and process stream-
line, but until a solution is adopted that reaches the core
concerns of all parties and offers an alternative pathway,
the status quo will remain steady.
Considering the framework of four consensus principles
for expanded access reform proposed by Sanghavi et al. –
Anticipation, Accessibility, Accountability, and Analysis
[10], the Mackey and Schoenfeld study and proposed re-
forms fall squarely within those principles. However, those
four suggestions should be joined by two additional “A”
principles to shape a truly disruptive force regarding ex-
panded access sufficient to constitute a valid alternative to
social media campaigns or right-to-try legislation: Access
and Advocacy.
Access
Mackey and Schoenfeld identified the common theme in
the patient case studies that the sought treatment was
viewed to be the patient’s last and best alternative (in
most cases) to save their life [1]. Without alternative
treatments, the only means by which a disruptive force
can address this concern is to provide an actual pathway
to drug access for appropriate patients. In a new expanded
access paradigm, companies can better provide that path-
way if they not only anticipate the requests, but have an
obligation to provide access in appropriate circumstances.
Not unlimited access, but a fair process at access.
The means, parties, and precise methods by which
access would be created would certainly be the subject
of debate; however, a broad continuum of both means –
legislative, collective, or voluntary, and parties affected –
the entire pharma industry, members of trade organiza-
tions, or individual companies, is possible. Proposed and
implemented examples of this already exist in the notion
of a national Expanded Access Institutional Review Board
suggested by Caplan and Moch (Moch being the CEO of
Chimerix during the Josh Hardy campaign) [9] and the in-
dependent Compassionate Use Advisory Committee being
piloted by Johnson & Johnson, who interestingly, has not
shied away from the term “compassionate use” as has be-
come common in their industry [11]. Even considering
potential legislative solutions, there is a continuum of
method possibilities from requiring EAPs during pivotal
trials under certain circumstances such as rapidly progres-
sing childhood diseases or linked to designations such as
the breakthrough designation, to individual Investigational
New Drug (IND) applications evaluated by an independent
commission. Even financial incentives to offer expanded ac-
cess at various stages could be one end of a broader access
spectrum. Given that the lack of treatment alternatives is
what forms the basis for the social media expanded access
campaigns, only a means of fairly providing sought therap-
ies, at least to some patients, would constitute a disruptive
force to the status quo.
Advocacy
Despite FDA assurances that expanded access uses have
never prevented the approval of a drug [14], companies
still fear the loss of millions of dollars invested in a drug
development program, whether as a result of FDA scru-
tiny or public perception affecting their stock price, if a
patient outside the controlled environment of a clinical
trial suffers a negative or even neutral response. However,
patients who wage sophisticated social media campaigns,
and gain public support behind them, usually do so be-
cause there is meat on the bone – safety and efficacy data
exist, at least in logical quantities, such that laymen see
the sought treatment as a viable alternative … to death.
Identifying the potentially appropriate cases for expanded
access (e.g. patients meeting defined safety criteria), and
what reforms might further assuage such fears, are a
necessary predicate to the design of a disruptive force
reform.
Conclusions and call for a disruptive force
The intersection of trends in social media, digital health,
and patient advocacy have created an environment where
expanded access campaigns offer the last, best hope to
save the lives of some patients. This trend will likely con-
tinue absent a disruptive force specifically addressing the
previously published concerns of anticipation, accessibility,
accountability, and analysis, but also access and advocacy,
such that it creates a meaningful pathway for appropriate
patients to access experimental treatments.
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Mackey and Schoenfeld recommend policy reforms
that respond to several of the concerns discussed above,
specifically they suggest an Expanded Access Task Force,
a centralized database of EAP policies and programs, a
single point of EAP contact, published criteria for ap-
proval under an expanded access program, and antici-
pated response times. In addition, they suggest that
economic incentives for implementing EAPs might be a
valuable way to encourage them.
While the authors’ recommendations represent poten-
tially worthwhile reforms, they should be viewed as pieces
of a new expanded access paradigm intended to constitute
a disruptive force in that space. Without evaluating
proposed reforms of disparate parties against the core
concerns of patients seeking access, and companies holding
access, to investigational therapies, it is impossible to assess
their true impact. Only a disruptive force offering an access
pathway and advocacy that addresses industry concerns
over potentially negative effects will alter the current trajec-
tory of social media-based expanded access campaigns as
the method of choice for desperate patients and caregivers.
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